Relapse prevention in bipolar 1 disorder: 18-Month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

British Journal of Psychiatry

Volumn 184, Issue APR., 2004, Pages 337-345

  Tohen, M ^a,b   Chengappa, K N R ^c   Suppes, T ^d   Baker, R W ^a   Zarate, C A ^e   Bowden, C L ^f   Sachs, G S ^g   Kupfer, D J ^c   Ghaemi, S N ^h   Feldman, P D ^a   Risser, R C ^a   Evans, A R ^a   Calabrese, J R ⁱ  

^a ELI LILLY AND COMPANY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h CAMBRIDGE HOSPITAL   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; OLANZAPINE; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LITHIUM; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; VALPROIC ACID;

EID: 11144354711     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.184.4.337     Document Type: Article

References (23)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
2. Banov, M. D., Zarate, C. A., Tohen, M., et al (1994) Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. Journal of Clinical Psychiatry, 55, 295-300.
3. Barnes, T. R. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672-676.
4. Bench, C. J., Lammertsma, A. A., Grasby, P. M., et al (1996) The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88.059-01) determined by positron emission tomography. Psychopharmocology, 124, 141-147.
5. Bowdan, C. L., Calabrese, J. R., Sachs, G., et al (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar 1 disorder. Archives of General Psychiatry, 60, 392-400.
6. Cuesta, M. J., Peralta, V. & Zarzuela, A. (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophrenia Research, 48, 17-28.
7. First, M. B., Spitzer, R. L., Gibbon, M., et al (1997) Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Patient Version. Washington, DC: American Psychiatric Press.
8. Goldstein, J. M., Cohen, L. S., Horton, N. J., et al (2002) Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Research, 110, 27-37.
9. Guy, W. (1974) ECDEU Assessment Manual for Psychopharmacology (Revised). Bethesda, MD: US Department of Health, Education and Welfare.
10. Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
11. Judd, L. L., Akiskal, H. S., Schettler, P. J., et al (2002) The long-term natural history of the weekly symptomatic status of bipolar 1 disorder. Archives of General Psychiatry, 59, 530-537.
12. Kane, J. M. & Smith, J. M. (1982) Tardive dyskinesia: prevalence and risk factors. 1959 to 1979. Archives of General Psychiatry, 39, 473-481.
13. Kinon, B. J., Basson, B. R., Gilmore, J. A., et al (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry, 62, 92-100.
14. Morgan, H. F. (1972) The incidence of depressive symptoms during recovery from hypomania. British Journal of Psychiatry, 120, 537-539.
15. Schooler, N. R. & Kane, J. M. (1982) Research diagnoses for tardive dyskinesia [letter]. Archives of General Psychiatry, 39, 486-487.
16. Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum. 212, S11-S19.
17. Strakowski, S. M., Keck, P. E., McElroy, S. L., et al (1998) Twelve-month outcome after a first hospitalization for affective psychosis. Archives of General Psychiatry, 55, 49-55.
18. Tohen, M., Stoll, A. L., Strakowski, S. M., et al (1992) The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome. Schizophrenia Bulletin, 18, 273-282.
19. Tohen, M., Chengappa, K. N., Suppes, T., et al (2002) Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Archives of General Psychiatry, 59, 62-69.
20. Tohen, M., Zarate, C. A., Hennen, J., et al (2003) The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. American Journal of Psychiatry, 160, 2099-2107.
21. Vieta, E., Goikolea, J. M., Corbella, B., et al (2001) Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter. open study. Journal of Clinical Psychiatry, 62, 818-825.
22. Young, R. C., Biggs, J. T., Ziegler, V. E., et al (1978) A rating scale for mania: reliability, validity, and sensitivity. British Journal of Psychiatry, 133, 429-435.
23. Zarate, C. A., Rothschild, A., Fletcher, K. E., et al (2000) Clinical predictors of acute response with quetiapine in psychotic mood disorders. Journal of Clinical Psychiatry, 61, 185-189.